India’s first indigenously developed COVID-19 vaccine COVAXIN is currently in phase II clinical trial. The vaccine is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). The company has sought the Drugs Controller General of India’s approval to start the large scale phase III clinical trial in the country. The early-stage human trials were conducted in 12 hospitals across the country, including AIIMS Delhi. Watch the video to know more about the COVAXIN trials from AIIMS Director Dr. Randeep Guleria.
Published: October 11, 2020 9:38 pm | Updated:April 14, 2021 7:15 pm